These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 19551801)

  • 1. Stereoselective HDAC inhibition from cysteine-derived zinc-binding groups.
    Butler KV; He R; McLaughlin K; Vistoli G; Langley B; Kozikowski AP
    ChemMedChem; 2009 Aug; 4(8):1292-301. PubMed ID: 19551801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Studies of benzamide- and thiol-based histone deacetylase inhibitors in models of oxidative-stress-induced neuronal death: identification of some HDAC3-selective inhibitors.
    Chen Y; He R; Chen Y; D'Annibale MA; Langley B; Kozikowski AP
    ChemMedChem; 2009 May; 4(5):842-52. PubMed ID: 19350613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional differences in epigenetic modulators-superiority of mercaptoacetamide-based histone deacetylase inhibitors relative to hydroxamates in cortical neuron neuroprotection studies.
    Kozikowski AP; Chen Y; Gaysin A; Chen B; D'Annibale MA; Suto CM; Langley BC
    J Med Chem; 2007 Jun; 50(13):3054-61. PubMed ID: 17539623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, and biological activity of boronic acid-based histone deacetylase inhibitors.
    Suzuki N; Suzuki T; Ota Y; Nakano T; Kurihara M; Okuda H; Yamori T; Tsumoto H; Nakagawa H; Miyata N
    J Med Chem; 2009 May; 52(9):2909-22. PubMed ID: 19419205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-alkylamides as a new class of synthetic histone deacetylase inhibitors. 1. Design, synthesis, biological evaluation, and binding mode studies performed through three different docking procedures.
    Mai A; Massa S; Ragno R; Cerbara I; Jesacher F; Loidl P; Brosch G
    J Med Chem; 2003 Feb; 46(4):512-24. PubMed ID: 12570373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and synthesis of thiazole-5-hydroxamic acids as novel histone deacetylase inhibitors.
    Anandan SK; Ward JS; Brokx RD; Denny T; Bray MR; Patel DV; Xiao XY
    Bioorg Med Chem Lett; 2007 Nov; 17(21):5995-9. PubMed ID: 17827005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring alternative Zn-binding groups in the design of HDAC inhibitors: squaric acid, N-hydroxyurea, and oxazoline analogues of SAHA.
    Hanessian S; Vinci V; Auzzas L; Marzi M; Giannini G
    Bioorg Med Chem Lett; 2006 Sep; 16(18):4784-7. PubMed ID: 16870438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, and evaluation of cyclic amide/imide-bearing hydroxamic acid derivatives as class-selective histone deacetylase (HDAC) inhibitors.
    Shinji C; Maeda S; Imai K; Yoshida M; Hashimoto Y; Miyachi H
    Bioorg Med Chem; 2006 Nov; 14(22):7625-51. PubMed ID: 16877001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and synthesis of non-hydroxamate histone deacetylase inhibitors: identification of a selective histone acetylating agent.
    Suzuki T; Matsuura A; Kouketsu A; Hisakawa S; Nakagawa H; Miyata N
    Bioorg Med Chem; 2005 Jul; 13(13):4332-42. PubMed ID: 15927839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis of N-hydroxycinnamides capped with a naturally occurring moiety as inhibitors of histone deacetylase.
    Huang WJ; Chen CC; Chao SW; Lee SS; Hsu FL; Lu YL; Hung MF; Chang CI
    ChemMedChem; 2010 Apr; 5(4):598-607. PubMed ID: 20209563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors.
    Tessier P; Smil DV; Wahhab A; Leit S; Rahil J; Li Z; Déziel R; Besterman JM
    Bioorg Med Chem Lett; 2009 Oct; 19(19):5684-8. PubMed ID: 19699639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thiol-based SAHA analogues as potent histone deacetylase inhibitors.
    Suzuki T; Kouketsu A; Matsuura A; Kohara A; Ninomiya S; Kohda K; Miyata N
    Bioorg Med Chem Lett; 2004 Jun; 14(12):3313-7. PubMed ID: 15149697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel HDAC6 isoform selective chiral small molecule histone deacetylase inhibitors.
    Smil DV; Manku S; Chantigny YA; Leit S; Wahhab A; Yan TP; Fournel M; Maroun C; Li Z; Lemieux AM; Nicolescu A; Rahil J; Lefebvre S; Panetta A; Besterman JM; Déziel R
    Bioorg Med Chem Lett; 2009 Feb; 19(3):688-92. PubMed ID: 19111466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and preliminary activity assay of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives as novel Histone deacetylases (HDACs) inhibitors.
    Zhang Y; Feng J; Liu C; Zhang L; Jiao J; Fang H; Su L; Zhang X; Zhang J; Li M; Wang B; Xu W
    Bioorg Med Chem; 2010 Mar; 18(5):1761-72. PubMed ID: 20171895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a series of substituted 2-piperazinyl-5-pyrimidylhydroxamic acids as potent histone deacetylase inhibitors.
    Angibaud P; Van Emelen K; Decrane L; van Brandt S; Ten Holte P; Pilatte I; Roux B; Poncelet V; Speybrouck D; Queguiner L; Gaurrand S; Mariën A; Floren W; Janssen L; Verdonck M; van Dun J; van Gompel J; Gilissen R; Mackie C; Du Jardin M; Peeters J; Noppe M; Van Hijfte L; Freyne E; Page M; Janicot M; Arts J
    Bioorg Med Chem Lett; 2010 Jan; 20(1):294-8. PubMed ID: 19906529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and synthesis of aryl ether and sulfone hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
    Pabba C; Gregg BT; Kitchen DB; Chen ZJ; Judkins A
    Bioorg Med Chem Lett; 2011 Jan; 21(1):324-8. PubMed ID: 21109435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone deacetylase inhibitors with a primary amide zinc binding group display antitumor activity in xenograft model.
    Attenni B; Ontoria JM; Cruz JC; Rowley M; Schultz-Fademrecht C; Steinkühler C; Jones P
    Bioorg Med Chem Lett; 2009 Jun; 19(11):3081-4. PubMed ID: 19410459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A series of novel, potent, and selective histone deacetylase inhibitors.
    Jones P; Altamura S; Chakravarty PK; Cecchetti O; De Francesco R; Gallinari P; Ingenito R; Meinke PT; Petrocchi A; Rowley M; Scarpelli R; Serafini S; Steinkühler C
    Bioorg Med Chem Lett; 2006 Dec; 16(23):5948-52. PubMed ID: 16987657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring bis-(indolyl)methane moiety as an alternative and innovative CAP group in the design of histone deacetylase (HDAC) inhibitors.
    Giannini G; Marzi M; Marzo MD; Battistuzzi G; Pezzi R; Brunetti T; Cabri W; Vesci L; Pisano C
    Bioorg Med Chem Lett; 2009 May; 19(10):2840-3. PubMed ID: 19359173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis, and evaluation of isoindolinone-hydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.
    Lee S; Shinji C; Ogura K; Shimizu M; Maeda S; Sato M; Yoshida M; Hashimoto Y; Miyachi H
    Bioorg Med Chem Lett; 2007 Sep; 17(17):4895-900. PubMed ID: 17588744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.